找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: ;

[復制鏈接]
樓主: invoke
21#
發(fā)表于 2025-3-25 04:33:47 | 只看該作者
22#
發(fā)表于 2025-3-25 09:40:25 | 只看該作者
https://doi.org/10.1007/978-3-642-28708-4. There are two agents that have been shown to slow the rate of deterioration in lung function in IPF. These two drugs, pirfenidone and nintedanib, have been variably approved in countries around the world.
23#
發(fā)表于 2025-3-25 12:46:21 | 只看該作者
https://doi.org/10.1007/978-3-540-85138-7oms and quality of life. However, there is no data to show that supplemental oxygen improves survival, although it can improve exercise capacity [1, 2]. Towards the late stages of IPF, high-flow oxygen devices such as an oxymizer or high humidity high-flow nasal cannula may be needed to maintain ade
24#
發(fā)表于 2025-3-25 16:05:36 | 只看該作者
https://doi.org/10.1007/978-3-030-96213-5of writing, there were 107 open and enrolling studies involving IPF diagnosis and treatment listed on .. Future discoveries are bound to occur at the genomic level, providing a clearer understanding of single nucleotide polymorphisms (SNPs) that predispose to the disease or predetermine the course i
25#
發(fā)表于 2025-3-25 22:26:12 | 只看該作者
Overview of Idiopathic Pulmonary Fibrosis,nary fibrosis (IPF) is a distinct subtype and one of the most common forms of ILD. It is a chronic fibrosing condition that is limited to the lungs, tends to be progressive in nature, and results in significant morbidity and mortality. IPF needs to be differentiated from the many other causes ILDs.
26#
發(fā)表于 2025-3-26 00:49:13 | 只看該作者
27#
發(fā)表于 2025-3-26 08:00:45 | 只看該作者
28#
發(fā)表于 2025-3-26 10:53:26 | 只看該作者
29#
發(fā)表于 2025-3-26 13:24:43 | 只看該作者
30#
發(fā)表于 2025-3-26 16:58:55 | 只看該作者
Treatment of Idiopathic Pulmonary Fibrosis,. There are two agents that have been shown to slow the rate of deterioration in lung function in IPF. These two drugs, pirfenidone and nintedanib, have been variably approved in countries around the world.
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 06:04
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
北碚区| 旌德县| 永春县| 紫金县| 龙海市| 方正县| 萝北县| 黔东| 宁城县| 漳州市| 卓尼县| 镇平县| 巴南区| 榆社县| 察雅县| 五河县| 昌平区| 兴文县| 马鞍山市| 拉萨市| 海门市| 晋宁县| 兴化市| 格尔木市| 万州区| 花莲市| 彩票| 南昌县| 罗平县| 桐梓县| 合作市| 楚雄市| 布拖县| 无极县| 岗巴县| 清水县| 扎囊县| 湖北省| 漳州市| 辽阳市| 突泉县|